Related references
Note: Only part of the references are listed.Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
Thomas Berger et al.
CNS DRUGS (2017)
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
Tjalf Ziemssen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Management of Idiopathic Thrombocytopenic Purpura in the Adult
James Lacey et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2017)
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
Eva Havrdova et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Alemtuzumab for the treatment of multiple sclerosis
Mark D. Willis et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2015)
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
Adam Cuker et al.
BLOOD (2011)
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
M. Cossburn et al.
NEUROLOGY (2011)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients
AJ Neylon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Share Paper
